Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis | ANNALS OF ONCOLOGY |